Bardoxolone Methyl
Bardoxolone Methyl is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities. Phase 3. (In Vivo) :Bardoxolone methyl (30 mg/kg, p.o.) decreases renal expression of megalin but not cubilin, increases creatinine clearance and urinary albumin-to-creatinine ratios, and induces Nrf2 cytoprotective targets in cynomolgus monkeys. Bardoxolone methyl induces overall favorable effects on the heart via its improvement in eGFR in both animal models and clinical trials.
Product Specifications
CAS Number
218600-53-4
Product Name Alternative
Bardoxolone methyl | NSC 713200 | RTA 402 | TP-155
Purity
>98% (HPLC)
Solubility
DMSO:21 mg/mL (41.52 mM) ; Ethanol:<1 mg/mL (<1 mM) ; Water:<1 mg/mL (<1 mM)
Smiles
O=C ([C@]1 (CC[C@@]2 (C) [C@]3 (C) CCC4C (C) (C) C (C (C#N) =C[C@]4 (C) C3=C5) =O) CCC (C) (C) C[C@]1 ([H]) [C@@]2 ([H]) C5=O) OC
Molecular Formula
C32H43NO4
Molecular Weight
505.69
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
GPR22, ID (GPR22, Probable G-protein coupled receptor 22)
